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Interleukin-6 (IL-6) is a proinflammatory cytokine up-regu-
lated by rhinovirus infection during acute exacerbations of
asthma and chronic obstructive pulmonary disease. The role of
IL-6 during exacerbations is unclear; however, it is believed IL-6
could contribute to airway and systemic inflammation. In this
study we investigate the effects of common asthma treatments
fluticasone propionate and 2 agonists salmeterol and salbu-
tamol on IL-6 production in BEAS-2B and primary bronchial
epithelial cells. Salmeterol and salbutamol enhanced rhinovi-
rus- and IL-1-induced IL-6 production; however, fluticasone
treatment caused a reduction of IL-6 protein and mRNA. Com-
bined activity of salmeterol and fluticasone at equimolar con-
centrations had no effect on rhinovirus or IL-1 induction of
IL-6. The induction of IL-6 by salmeterol was dependent upon
the 2 receptor and could also be induced by cAMP or cAMP-
elevating agents forskolin and rolipram. Using transfection of
IL-6 promoter reporter constructs, dominant negativemutants,
and electromobility shift assays, it was found thatNF-Bwas the
only transcription factor required for rhinovirus induction of
IL-6 gene expression. Salmeterol caused an augmentation of
rhinovirus-induced promoter activation via a mechanism
dependent upon the c/EBP and/or CRE (cyclic AMP response
element) cis-acting sites. The suppressive effect of FP was
dependent upon distinct glucocorticoid response element
sequences proximal to the transcriptional start site within the
IL-6 promoter. The data demonstrate that 2 agonists can aug-
ment IL-6 expression by other stimuli in an additive manner via
cyclic AMP and that the negative effect of steroids is mediated
by glucocorticoid response elements within the IL-6 promoter.
Asthma and chronic obstructive pulmonary disease
(COPD)2 are inflammatory diseases of the airway. Recent evi-
dence suggests a large proportion of exacerbations of both dis-
eases are precipitated due to viral infections (1–7), and themost
prominent respiratory virus associated with either disease is
human rhinovirus (RV) (8–10). Rhinovirus infects the bron-
chial epitheliumand induces a variety of proinflammatory cyto-
kines, chemokines, and adhesion molecules, serving to attract
inflammatory cells and prolong local inflammation within the
airway (11, 12). Among the many cytokines induced, IL-6, a
pleiotropic cytokine, is commonly associated with both dis-
eases (13–15). Although IL-6 has inflammatory, anti-inflam-
matory, and immunomodulatory properties, its exact role in
either disease remains unclear.
Adequate treatment of asthma and COPD exacerbations
remains an important therapeutic goal. Inhaled corticosteroids
(GCs) and long acting 2 agonists (LABAs) are common treat-
ments for asthma and COPD and exacerbations of these dis-
eases, often used in combination. However, these treatments
are only partially effective, reducing rates of asthma exacerba-
tions by 40% and less so for COPD (16, 17). A thorough under-
standing of the actions and interactions of these treatments at
the physiological, cellular, and molecular level is a major
research objective, allowing a more careful application of these
treatments to appropriate patients.
Several studies have demonstrated the anti-inflammatory
potential of GCs; however, their mode of action has been vig-
orously debated (18). Recent evidence also demonstrates that
LABAs can enhance the anti-inflammatory action of steroids
(19–22). LABAs, however, can affect the expression of other
genes via cAMP-dependent pathways, such as the induction of
IL-6 in airway smooth muscle cells (ASM) (23). The human
IL-6 promoter contains several different cis-acting sites proxi-
mal to the TATA box, including NF-B, AP-1, CCAAT
enhancer-binding protein (c/EBP), and a cyclic AMP response
element (CRE), and all have been implicated in IL-6 transcrip-
tion using a range of different stimuli (23–25).
Because bronchial epithelial cells express both glucocortcoid
receptors (GR) and 2 receptors and are target cells for com-
bined GC and 2 agonist therapy in vivo, we have investigated
themodulation of RV- and IL-1-induced IL-6 by pretreatment
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with salmeterol (SM) and fluticasone propionate (FP) in pri-
mary bronchial epithelial cells and cell lines. RV induced IL-6
via IB kinase (IKK)- and NF-B and was augmented via SM
by CRE and c/EBP binding transcription factors in a cAMP-
dependentmanner. FP decreased RV-induced IL-6 via negative
glucocorticoid response elements (GRE), proximal to the
TATA box, confirming IL-6 as one of few steroid susceptible
genes that is controlled via a negative GRE. Interestingly, in
combination, RV induced IL-6 mRNA and protein levels were
unaltered, showing that the effect of one agent negates the
other. Finally, the data further demonstrate that2 agonist have
biological effects other than suppressing gene transcription in
collaboration with GCs.
EXPERIMENTAL PROCEDURES
Tissue Culture and Viruses—BEAS-2B cells were obtained
from the European Collection of Cell Cultures (ECACC
95102433). Cells were grown in RPMI 1640 media supple-
mented with Glutamax (Invitrogen) with 10% fetal calf serum
(FCS, Invitrogen) buffered with 1% sodium bicarbonate
(Invitrogen) and 0.075% HEPES (Invitrogen). Cells were grown
at 37 °C in a humidified incubator using 175-cm2 flasks and split
when confluent, approximately 3 times aweek. RV serotypes 16
and 1Bwere grown inOhioHeLa cells and titrated on confluent
HeLa cells to ascertain TCID50 (2). RV16 was 1  107, and
RV1B was 107 TCID50/ml. The identity of all RVs was con-
firmed by titration onHeLa cells and neutralization using sero-
type-specific antibody. UV inactivation was performed essen-
tially as previously described (26, 27), and filtered virus was
obtained by spinning HeLa cell supernatants containing RV
through a 30-kDamembrane (Millipore, Stonehouse Glouster-
shire, UK) at 10,000 g in a microcentrifuge (Heraeus) for 5 min.
Plasmids, Site-directed Mutagenesis, and Reagents—Recom-
binant human IL-1 was purchased from R&D Systems
(Abingdon, UK), dissolved in phosphate-buffered saline at 10
g/ml, and stored at20 °C. Salbutamol (SB), propranolol, for-
skolin, and rolipram were purchased from Sigma-Aldrich, dis-
solved in dimethyl sulfoxide (Me2SO) at a concentration of 0.1
M, and stored at 20 °C. SM and FP (GlaxoSmithKline) were
also dissolved inMe2SO, at 0.1 M. Dibutryl-cAMPwas also pur-
chased from Sigma-Aldrich and made up at 0.1 M in water.
Before use, stocks were dissolved in RPMI 1640 medium with
2% FCS (infection media) at the required concentrations. IL-6
promoter-reporter constructs consisted of various mutations
or deletions of the full-length IL-6 promoter (651 bp) fused to
firefly luciferase (24). We constructed IL-6 GRE 651 using a
site-directed mutagenesis kit (Stratagene, La Jolla CA) and
mutant oligos 5-GACTGGAGATGTCTGAGAATTCTTCG-
AATTCCGAGGTCGACGGT-3 and 3-CTGACCTCTACAG-
ACTCTTAAGAAGCTTAAGGCTCCAGCTGCCA-5, where
mutations are presented underlined and in bold. IL-6 CRE651
was made using the oligonucleotides 5-GCGATGCTAAAGG-
GATCCACATTGCA-3 and 3-CGCTACGATTTCCCTAGG-
TGTAACGTG-5, according to previously published methods
(28, 29). All mutant constructs were verified by dideoxy termi-
nator sequencing. A dominant negative (DN) mutant of IB
under control of the CMVpromoter was purchased fromClon-
tech (Oxford, UK). pcDNA3.1 and a construct encoding -ga-
lactosidase constitutively expressed by the CMV promoter
(pCMVSPORT--gal), were purchased from Invitrogen. All
plasmidswere grown in Escherichia coliXL-1 blue, and plasmid
DNA was prepared using a Maxiprep method (Qiagen, Craw-
ley, UK) and stored at80 °C at 1 g/l.
Transient Transfection of BEAS-2B Cells—Cells were seeded
at 1.7  105 cells per well in 12-well plates (Nunc, Roskilde,
Denmark), pre-coated with type IV calf collagen solution (Sig-
ma-Aldrich), diluted 1/10 in phosphate-buffered saline, and left
to grow for 48 h in RPMI 1640 with Glutamax (Invitrogen)
supplemented with 10% FCS. Cells were transiently transfected
with 1 g of DNA per well consisting of either 0.8 g of a IL-6
promoter-reporter construct and 0.2 g of pCMVSPORT--
gal, (Invitrogen). Cells were also transfected with 0.7 g of the
IL-6 reporter and 0.1 g or either a DN of IB or empty vector
pcDNA3.1 and 0.2 g of -galactosidase. Transfection made
use of 3 l per well of Superfect (Invitrogen) according to the
manufacturer’s recommended protocol. DNA-Superfect com-
plexes remaining on the cells for 3 hwerewashed off with 0.5ml
of phosphate-buffered saline/well, and 1 ml/well of RPMI 1640
media (Invitrogen) with 10% FCS, and the cells were incubated
overnight at 37 °C. Cells were then placed in infectionmedia for
4 h and treated with SM or FP or medium before infection with
RV16. Protein lysates were harvested at 72 h post-infection.
RV Infection and IL-1 Treatment of Bronchial Epithelial
Cells—For the induction and study of proteins, BEAS-2B cells
were counted using trypan blue exclusion and seeded in 12-well
plates (Nunc) at 1.7 105 cells/well in RPMI 1640 and 10% FCS
medium and allowed to adhere for 24 h. BEAS-2B cells were
thenplaced in infectionmedia overnight.Monolayerswere pre-
treated with SM, SB, and FP at various doses, diluted in infec-
tion media, or treated with medium for 1 h. All wells were nor-
malized for the presence of Me2SO. Cultures were then
stimulated with 0.2 ml of RV16 or RV1B (m.o.i. of 1–4) or 1
ng/ml IL-1 (R&D Systems) for 1 h with shaking at room tem-
perature. Viruses and IL-1 were then removed and replaced
with 1 ml of infection media and incubated for 24 h. When
using pharmalogical inhibitors, each inhibitor was diluted in
infection medium and placed on the cells for 2 h before treat-
ment with SM and SB or infection with RV16. All supernatants
were stored at 80 °C for analysis. For induction of promoter
activation, BEAS-2B cells were transfected as above and then
placed in infection media for 4 h. Cells were then treated with
SM and FP at the required concentrations or medium for 1 h and
then with 0.2 ml of RV16 (m.o.i. 1–4) or medium for 1 h with
shaking at room temperature. For RV-infected wells, infection
media containing SM and or FP was then placed on the cells and
incubated for 72 h to allow expression of the reporter gene.
Quantitative ELISA for IL-6—Supernatants were tested for
the amounts of IL-6 by ELISA using commercially available
paired antibodies and standards (R&D Systems) according to
the manufacturer’s recommendations. One hundred microli-
ters of supernatant were tested in duplicate and compared with
a standard curve, allowing quantification of each sample. The
sensitivity of the assay was 7 pg/ml.
Reporter Gene Assays—Cellular extracts were prepared
using commercially available reagents for the measurement
of luciferase protein (Promega, Madison, WI). Luciferase
Modulation of Rhinovirus-induced IL-6
MAY 25, 2007•VOLUME 282•NUMBER 21 JOURNAL OF BIOLOGICAL CHEMISTRY 15367
 at Im
perial College London on June 15, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
activity was measured using commercially available reagents
(Promega) and a AutoLumat LB953 luminometer (Berthold
Systems) for 10 s. All luciferase measurements were normal-
ized to -galactosidase expression using a commercially
available enzymatic assay (Promega) at 420 nm in a Spectro-
max plate reader (Molecular Devices Ltd, Wokingham UK).
Luciferase data were normalized by expressing relative lucif-
erase units over -galactosidase measurements (absorbance
at 420 nm).
RNA Extraction and Quantitative Reverse Transcription-
PCR—Total RNA was extracted (RNeasy kit, Qiagen), and 2 g
was used for cDNA synthesis (Omniscript RT kit, Qiagen).
Quantitative PCR was carried out using specific primers and
probes for IL-6 (sense, 5-CCA GGA GCC CAG CTA TGA
AC-3; antisense, 5-CCC AGG GAG AAG GCA ACT G-3;
probe, 5-FAM CCT TCT CCA CAA GCG CCT TCG GT-6-
carboxytetramethylrhodamine-3)
and 18 S rRNA (sense, 5-CGC
CGC TAG AGG TGA AAT TCT-
3; antisense, 5-CAT TCT TGG
CAA ATG CTT TCG-3; probe,
5-FAM ACC GGC GCA AGA
CGG ACC AGA-6-carboxytetra-
methylrhodamine-3). Reactions
consisted of 12.5 l of 2 Quanti-
Tect Probe PCR Master Mix (Qia-
gen) and 300 nM sense and 900 nM
antisense primer and 175 nM
probe (IL-6) or 300 nM concentra-
tions each of primer and 175 nM
probe (18 S rRNA). Two l of
cDNA (18 S 2 l diluted 1/100)
was made up to 25 l with nucle-
ase-free water (Promega). Reac-
tions were analyzed (ABI 7000
TaqMan, Foster City CA) at 50 °C
for 2 min, 94 °C for 10 min, and 45
cycles of 94 °C for 15 s and 60 °C
for 15 s. IL-6 expression was nor-
malized to 18 S rRNA and pre-
sented as copies of IL-6 mRNA/g
of total RNA using a standard
curve based on amplification with
plasmid DNA.
Nuclear and Cytoplasmic Protein
Harvest—BEAS-2B cells were grown
in six-well plates and prepared as for
reporter and protein experiments.
Cells were pretreated SM, FP, or
medium and then infected with
RV16 for 20 min with shaking, and
protein extracts were harvested at
30 min post-infection. Nuclear and
cytoplasmic protein fractions were
harvested using protein extraction
reagents (Pierce) supplemented
with protease inhibitors (Pierce).
Electromobility Shift Assay
(EMSA)—Electromobility shift assay (EMSA) was performed
using a nonradioactive EMSA kit (LightShiftTM, Pierce)
according to the manufacturer’s recommended protocol. Oli-
gonucleotides were designed on the NF-B site within the
human IL-6 promoter including surrounding sequences; (for-
ward, 5-ATCAAATGTGGGATTTTCCCATGAG-3; reverse,
5-CTCATGGGAAAATCCCACATTTGAT-3). Oligonucleo-
tides with mutated NF-B sites were also designed; forward,
5-ATCAAATGTGGGATTTTAGACTGAG-3; reverse, 5-
CTCAGTCTAAAATCCCACATTTGAT-3, with mutated
nucleotides shown in underlined boldface type.
Statistics—All data were analyzed using one-way ANOVA at
a 95% confidence interval and, if significant, pin-pointed with
Bonferroni’s multiple comparison test or pin-pointed using a
two-tailed t test. Data were accepted as significantly different
when p 0.05.
FIGURE 1. Induction of IL-6 by rhinovirus and IL-1 andmodulation by SM and FP in BEAS-2B cells. RV16
(A) and RV1B (B) induced IL-6 protein, and this could be decreased either by filtration through a 30-kDa filter or
by UV irradiation. ***, p 0.001 versus RV infected. C, IL-1 caused a dose-dependent increase in IL-6 protein
measured at 24 h. ***, p  0.001 versus medium. RV16-induced IL-6 protein was suppressed by FP (D) or
increased by SM (E) in a dose-dependentmanner and also increased by SB (F) at 10 nM. *, p 0.05; **, p 0.01;
***, p  0.001 (versus RV16 infected or medium-treated-only cells). All IL-6 protein measurements were per-
formed by ELISA; n 4 experiments.
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RESULTS
HumanRhinovirus and IL-1 Stimulate IL-6 Protein inBron-
chial Cells in Vitro—We have used RV16 and RV1B and the
proinflammatory cytokine IL-1 as examples of proinflamma-
tory agents that can lead to IL-6 production in bronchial epi-
thelial cells. Both major RV16 and minor group RV1B viruses
produce IL-6 in BEAS-2B cells after 24 h of culture (Fig. 1,A and
B). The induction of IL-6 was due to virus replication and infec-
tion rather than other constituents of the HeLa supernatant as
UV-inactivated, and filtered virus preparations gave signifi-
cantly lower IL-6 production (p  0.01). Fig. 1C shows that
IL-1 induces IL-6 after 24 h of culture in a dose-dependent
manner.
Modulation of Rhinovirus and IL-1 Induced IL-6 by 2 Ago-
nists and GCs in Both BEAS-2B and NHBE Cells—The cortico-
steroid FP and 2 agonists SM and SB were used to investigate
whether or not asthma therapies were effective at alleviating
RV- and IL-1-induced IL-6 production. Fig. 1 demonstrates
the ability of each treatment alone to affect spontaneous and
RV16-induced IL-6 protein production after 24 h. FP sup-
pressed bothRV16-induced and spontaneous IL-6 in a dose-de-
pendent manner (p  0.001, versus control cells, Fig. 1D). In
contrast, SM greatly augmented spontaneous and RV16-in-
duced IL-6 production at 1 and 10 nM (p 0.01 and p 0.001,
respectively, versus RV16 infected, untreated controls, Fig. 1E).
At 10 nM SB gavemodestly augmented RV16-induced IL-6 pro-
duction (p 0.05 versus RV16-infected, untreated control, Fig.
1F) but did not affect the basal level of IL-6 production in cul-
tures treated only with medium. In primary NHBE cells, FP
suppressed RV1B-induced IL-6 protein in a dose-dependent
manner (Fig. 2A), whereas SM augmented RV1B-induced IL-6
protein in a dose-responsive manner (Fig. 2B).
BEAS-2B cells were then pretreated with different combina-
tions of SM and FP at 1 or 0.1 nM (Table 1). At 1 nM SM aug-
mented RV16-, RV1B-, and IL-1-induced IL-6, whereas1 nM
FP led to suppression of IL-6 with the same stimuli.When used
in combination, the activities of SM and FP were diminished
and had little affect when compared with RV16-, RVIB-, or
IL-1 alone-treated cultures (p 0.05). When the FP concen-
tration was reduced to 0.1 nM, FP alone had little affect on
virus and IL-1-induced IL-6 protein. When used in combi-
nation with SM at 1 nM, the augmentative effects of SM were
observed again despite the presence of the steroid and gave
significant increases in IL-6 when using IL-1 (p 0.05) and
RV16 (p  0.001) but not RV1B (p  0.05). Similar results
were observed with NHBE cells (Table 2) with 1 nM SM aug-
menting RV1B-induced IL-6 (p 0.001) and 1 nM FP reduc-
ing RV1B-induced IL-6 (p 0.01), and in combination, IL-6
levels were elevated significantly compared with untreated
RV1B infected cells (p  0.01).
SM and RV16 Induce IL-6 mRNA but with Different Kinet-
ics—Time course experiments in BEAS-2B cells were designed
to investigate the transcriptional induction of IL-6 in BEAS-2B
cells. RV16 induced IL-6 mRNA at 24–72 h when compared
withmedium-treated cells (p 0.01, Fig. 3A), still rising at 72 h.
In contrast, SM induced IL-6mRNAmuch earlier, significantly
FIGURE 2.Modulation of RV1B induced IL-6 by SM and FP in NHBE cells.
RV1B-induced IL-6 protein was suppressed by FP (A) and increased by SM (B)
in a dose-dependent manner. *, p 0.05; **, p 0.01 (versus RV16-infected
cells). All IL-6 protein measurements were performed by ELISA; n  5
experiments.
TABLE 1
Modulation of IL-6 protein by SM or FP (0.1–1 nM) alone and in combination
BEAS-2B cells were pretreated with SM, FP, or SM and FP and treated with either IL-1 or RV. IL-6 protein was measured by ELISA.
% IL-6 release in BEAS-2B cells
Pretreatment with 1 nMFP Pretreatment with 0.1 nMFP
Untreated SM FP SMFP SM FP SMFP
mean	 S.E.
IL-1 100 293.8	 71.3a 45.3	 2.7c 94.0	 17.3d 226.3	 43.9a 81.38	 11.3d 202.9	 34.1a
RV16 100 286.5	 64.9a 49.6	 11.9b 73.1	 18.3d 408.2	 32.6c 101.7	 11.9d 381.4	 18.3c
RV1B 100 402.3	 54.5a 37.5	 5.6c 106.8	 16.6d 284.9	 67.9v 98.7	 9.0d 218.7	 51.8d
a p 0.05.
b p 0.01.
c p 0.001.
dNS, not significant.
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different from medium-treated cells, and peaked at 8 h post-
treatment (p 0.01, Fig. 3B).
SM Induction of IL-6 Is cAMP- and -Receptor-dependent—
The SM induction of IL-6 was blocked using the -receptor
antagonist propranolol in a dose-dependent manner (Fig. 4A).
Dibutryl cAMP augmented RV16-induced IL-6 and also
induced IL-6, statistically significant at 1 mM (p  0.01 com-
pared with RV16-infected and p  0.05 compared with medi-
um-treated Fig. 4B). Furthermore, the adenylate cyclase activa-
tor forskolin also induced IL-6 in a dose-dependent manner
(Fig. 4C). Finally the phosphodiesterase inhibitor rolipram also
induced IL-6 in BEAS-2B cells (Fig. 4D). Rolipram and cAMP
also induced IL-6 mRNA at 8 and 24 h post-treatment in
BEAS-2B cells when compared with cells treated with medium
(Table 3).
Importance of NF-B in Rhinovirus-induced IL-6—Because
various data implicate the transcription factor NF-B in RV-
induced proinflammatory cytokine gene expression (25, 30), we
investigated the role of NF-B in RV-induced IL-6 production.
The role of NF-B was first assessed using mutated or deleted
constructs of the human IL-6 promoter (depicted in Fig. 5A) in
transient transfection experiments in BEAS-2B cells. RV16 up-
regulated the IL-6 promoter 24–72 h post-infection (data not
shown), with maximal promoter activation occurring at 72 h.
RV16 up-regulated a651-bp fragment of the human IL-6 pro-
moter compared with medium (p 0.001), and this induction
was abrogated when using promoter constructs with an NF-B
mutation (NF-B), both NF-B and c/EBP mutation (NF-
B/cEBP, p  0.001 compared with induction with the
651-bp fragment, Fig. 5B). There was no difference between
induction with the 651-bp fragment and the 160-bp frag-
ment or with the IL-6 promoter with a mutated AP-1 site
(AP-1) or a promoter with mutated c/EBP site (c/EBP). IL-6
promoter activation was also inhibited using a DN mutant of
IB,which preventsNF-Bnuclear translocation (Fig. 5C). IL-6
promoter activation was inhibited in the presence of the IB
DN compared with cells transfected with IL-6 promoter and
empty vector control (p  0.001). Using EMSA- on RV16-in-
fected nuclear extracts and oligonucleotides designed on the
NF-B site within the human IL-6 promoter, a protein-oligo-
nucleotide band shift was observed thatwas out-competedwith
excess unlabeled oligonucleotide (50 and 100 excess). How-
ever, the band was not competed by unlabeled oligonucleotide
having mutations within the NF-B binding site (Fig. 5D).
Finally, the crucial role of NF-B was confirmed, and a role for
the IB kinase IKK- using a pharmalogic inhibitor of IKK-,
AS602868, which reduced RV16-induced IL-6 protein release
in a dose-dependent manner (p  0.001 versus infected,
untreated control; Fig. 5E).
FP and SM Regulate Rhinovirus-induced IL-6 via Distinct
Cis-acting Elements—Because FP down-regulated IL-6 pro-
tein levels, whereas SM induced IL-6 protein and mRNA, we
used IL-6 promoter-reporter constructs to determine
whether these effects were mediated by distinct cis-acting
elements. FP reduced IL-6 promoter activation in a dose-de-
pendent manner (Fig. 6A). Similar results were observed
when using a 651-bp fragment of the IL-6 promoter or a
160-bp fragment (p  0.05 compared with RV16 infected,
Fig. 6B). To determine whether a TATA proximal negative
GRE (nGRE) was involved in FP-mediated suppression of the
IL-6 promoter activation, we produced a 651-bp fragment
of the promoter with a mutated GRE (651 GRE, Fig. 6C).
When compared with the parental 651-bp fragment, this
mutated promoter was not steroid-responsive (p  0.05
compared with the 651-bp promoter) but was still RV16-
inducible (Fig. 6D).
These same IL-6 promoter constructs were used to deter-
mine any cis-acting sites capable of mediating SM augmen-
tation of RV16-induced IL-6. SM enhanced RV16-induced
FIGURE 3. Time course of RV16 and SM-induced IL-6 mRNA synthesis in
BEAS-2B cells. A, RV1B induced IL-6 mRNA in a time-dependent manner,
peaking at 48–72 h. B, SM induced IL-6 mRNA in a time-dependent manner,
peaking at 8 h. **, p 0.01; ***, p 0.001 (versus medium-treated cells). All
IL-6mRNAmeasurements were performed by quantitative reverse transcrip-
tion-PCRnormalized to constitutive 18 S rRNAexpression;n 5 experiments.
TABLE 2
Modulation of IL-6 protein by SM or FP (0.1–10 nM) alone and in
combination
NHBE cells were pretreated with SM, FP, or SM and FP and infected with RV1B.
IL-6 protein was measured by ELISA. NS, not significant.

FP
% IL-6 release in NHBE cells
(pretreatment with FP and SM at 1 nM)
RV1B SM FP SMFP
nM mean	 S.E.
0.1 100 294.9	 57.5a 89.3	 11.9 442.4	 123.3a
1 100 353.0	 23.9c 51.5	 6.7 180.2	 25.0a
10 100 313.1	 25.1b 46.7	 2.2 110.9	 42.7d
a p 0.05.
b p 0.01.
c p 0.001.
dNS, not significant.
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IL-6 promoter activation using the 651-bp construct (p 
0.05, Fig. 7A) but not the 160-bp construct (lacking AP-1
and CRE) or 651-bp constructs with a mutated NF-B,
NF-B, and c/EBP or c/EBP sites (p  0.05). To confirm the
importance of the CRE or c/EBP sites, 651-bp constructs
with mutated CRE sites were designed (651CRE, Fig. 7B).
Further experiments suggested that it is the c/EBP site that is
required for the SM augmentation of RV16-induced IL-6, as
there was no significant augmentation of RV16-induced
reporter activation with 651 c/EBP (p 0.05); however, the
651 CRE construct was still responsive to SM treatment
(p  0.01, Fig. 7C).
DISCUSSION
IL-6 is a pleiotropic cytokine
associated with inflammatory lung
diseases including asthma and
COPD. The biological effects of
IL-6 include B-lymphocyte mat-
uration, monocyte-macrophage
differentiation, induction of the
acute phase response in hepato-
cytes, and other immunomodula-
tory properties. In this study we
have analyzed the transcriptional
regulation of the IL-6 gene by rhi-
novirus and the modulation of this
gene by both GCs and 2 agonists.
The IL-6 promoter is well charac-
terized and consists of several cis-
acting sites that have been shown to
be responsive to various stimuli.
Several studies have shown the
NF-B, AP-1, c/EBP (NF-IL-6), and
CRE sites to bind their respective
trans-activating proteins in a range
ofmodel systems (23, 24); therefore,
the human IL-6 promoter is an
excellent model system of a com-
plex human gene relevant to human
disease. Our data and others (25, 31)
show that RV requires NF-B for
IL-6 promoter inducibility, and we
have further shown that NF-IL6 or
AP-1 is not required in BEAS-2B
cells. The NF-B or Rel family of
transcription factors are cytosolic proteins implicated in the
regulation of more than 100 different genes (32). Activation of
NF-B occurs via phosphorylation, ubiquitination, and then
degradation of its cytosolic inhibitor, IB, via several different
kinases, notably IKK-/. Once free from its inhibitor, NF-B
translocates to the nucleus and binds to recognition siteswithin
promoters of NF-B-responsive genes. The activation of
NF-B by RV is well documented (31, 33, 34), and NF-B has
also been implicated in the transcriptional regulation of many
genes induced by RV (26, 30, 34–36). The present study also
supports evidence that IL-6 transcription via RV occurs in a
IKK--dependent manner.
RV-induced IL-6 was sensitive to pretreatment with the GC,
FP. GCs act through a range of different mechanisms and can
either induce or down-regulate the expression of many differ-
ent genes. Induction of GC responsive genes, such as mitogen-
activated kinase phosphatase-1 andToll-like receptor-2, occurs
via GRE elements within promoters of affected genes (37–39).
Suppression of gene transcription is the most well studied
action of GCs, and this may occur through several postulated
mechanisms. GCs have been shown to make protein-protein
interactions with various proinflammatory transcription fac-
tors, notably NF-B and AP-1 in the process of transrepression
(40–43), thus preventing the transcription factors from bind-
FIGURE 4. Induction of IL-6 by SM is-receptor-dependent and requires cAMP in BEAS-2B cells. A, SM-in-
duced IL-6 protein at 24 h was blocked in a dose-dependent manner by propranolol a -receptor antagonist;
*, p 0.05; **, p 0.01 (versusmedium-retreated SM-treated). B, cAMP induced IL-6 protein and augmented
RV16-induced IL-6 in a dose-dependent manner; *, p  0.05; **, p  0.01, (versus medium-treated only or
RV-infected only). The adenylate cyclase activator forskolin (C) and the phosphodiesterase inhibitor rolipram
(D) induced IL-6 protein at 24h in adose-dependentmanner. *, p 0.05; ***,p (0.001 versusmedium-treated
cells). All IL-6 protein measurements were performed by ELISA; n 3–4 experiments.
TABLE 3
Induction of IL-6 mRNA by cAMP or rolipram
BEAS-2B cells were treated withmedium, rolipram, or cAMP for 8 or 24 h, and IL-6
mRNA was measured by TaqMan reverse transcription-PCR.
Treatment
Copy number of IL-6 mRNA
per g of total RNA
8 h 24 h
mean	 S.E.
Medium 6,581	 1,294 9,541	 2,328
Rolipram 60,615	 20,587a 74,275	 17,090b
cAMP 119,099	 45,724b 153,032	 38,364c
a p 0.05.
b p 0.01.
c p 0.001.
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ing their cis-acting sites and recruiting co-activators to the
transcription initiation complex. GCsmay also modulate chro-
matin by enhancing histone deacetylation (44) and decreasing
histone acetylation (45), causingDNA to remain protein bound
and preventing transcription factor access to unwound DNA
and, hence, accessible cis-acting sites.
Careful scrutiny of the IL-6 promoter has identified at least
two nGREs, at170 bp relative to the transcriptional start site
and one close to the TATAbox and transcription start site (46).
Upon steroid treatment, these sites
confer steroid sensitivity in HeLa
cells, indicating IL-6 is different
from most genes in that promoter-
specific nGRE sites act to down-reg-
ulate transcription rather than
enhance it (46). We have confirmed
this initial study by showing that
suppression of RV-induced IL-6
occurs via a single nGRE site near
the TATA box and transcription
start site (5 to 10). Mutation of
this site using site-directed
mutagenesis resulted in a loss of FP
sensitivity to the651-bp fragment
of the IL-6 promoter. A construct
(160-bp fragment) lacking
another GRE site located further
upstream of the TATA box at posi-
tion 170 bp was still FP-sensitive,
indicating that the downstream
TATA proximal site was crucial in
mediating GC suppression of
RV-induced IL-6. AnnGRE element
at this position could function by
binding the GR dimer and by block-
ing RNA polymerase activity at the
transcription start site via steric hin-
drance or by preventing association
of transcription factors with their
co-activators CBP or p300 and,
hence, association of the IL-6
enhancersome. Further experi-
ments are required to establish the
finer details of how this unique
sequence interacts with the GR and
affects IL-6 transcription.
Because GCs are used in con-
junction with LABAs, we were
interested in the effects of SM on
IL-6 alone and in conjunction with
FP. We found that SM and to a
lesser extent SB- and cAMP-ele-
vating agents to be efficient induc-
ers of IL-6 protein and mRNA.
This was not due to a general toxic
response of bronchial epithelial
cells to SM or other agents,
because in the same experiments
SM had no effect on IL-1- and RV-induced CXCL8/IL-8 or
RANTES (regulated on activation normal T cell expressed
and secreted)/CCL5, and in combination with FP, the com-
bination significantly down-regulated these genes superior
to FP treatment alone both in BEAS-2B cells and primary
bronchial epithelial cells (22). In the present study, SM
induced IL-6 in both bronchial epithelial cell lines and pri-
mary bronchial epithelial cells, indicating this was not sim-
ply a feature of the BEAS-2B cell line.
FIGURE 5. Importance of NF-B in RV16-induced IL-6 in BEAS-2B cells. A, schematic diagram of TATA
proximal cis-acting sites within the human IL-6 promoter. The wild type 651-bp parental promoter was
mutated or deleted to give the corresponding reporter promoter constructs with altered transcription factor
binding sites. B, the 651-bp promoter was induced by RV16 at 72 h post-infection, and deletion of NF-B
sequences but not AP-1 CRE or c/EBP caused a loss of promoter activity. **, p  0.01; ***, p  0.001 (versus
651-bp promoter or as indicated). C, transfection of the 651-bp promoter with an IBDNbut not empty vector
caused suppression of IL-6 promoter activation. ***, p 0.001 versus empty vector control.D, protein extracts
from RV16-infected cells but not medium-treated cells caused a shift in electrophoretic pattern of a labeled
oligonucleotide designed on the NF-B binding sequence from the IL-6 promoter. E, the IKK- inhibitor
AS602868 suppressed RV16 and basal IL-6 protein at 24 h in a dose-dependent manner. **, p 0.01; ***, p
0.001 versus (RV16-infected-only cells or medium-treated-only cells). All luciferase measurements were nor-
malized to constitutive -galactosidase measurements and IL-6 protein was performed by ELISA n  4–6
experiments.
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The effect of SMon IL-6 induction became clearer after care-
ful examination of the IL-6 promoter and also consideration of
the literature on IL-6 induction derived from airway smooth
muscle. Two studies have investigated the effects of 2 agonists
on IL-6 in ASM and also showed these agents to be strong
inducers of IL-6 (23). This can be explained by the IL-6 pro-
moter, which is cAMP-responsive. At position166 to154, a
CRE element exists of sequence AGGACGTCACAT that con-
fers LABA inducibility in ASM cells (23). The IL-6 promoter
also contains a c/EBP orNF-IL6 site (ATTGCACAAT,154 to
146) that may also respond to cAMP-mediated pathways
(47). These two sites both bind bZIP transcription factors; CRE
binds ATF/CREB family members, whereas c/EBP binds c/EBP
family members. Initial experiments clearly showed that IL-6
was induced by cAMP- or cAMP-elevating agents and that pro-
moters truncated to 160 bp resulted in diminished ability of
SM to enhance RV16-induced IL-6 promoter activation in
BEAS-2B cells. Further experiments identified the c/EBP site
rather than the CRE site of this region to be absolutely required
for SM augmentation of IL-6 promoter activation. It was sur-
prising that the 160-bp fragment
(lacking CRE), but not 651 CRE,
gave diminished IL-6 promoter
inducibility by SM. These discrep-
ancies could be explained by the
160-bp fragment and the 651
CRE not having exactly the same
sequence with respect to nucleo-
tides surrounding the CRE element,
such that surrounding sequences
missing in the 160-bp fragment,
but intact in the 651 CRE mutant,
could influence transcription factor
binding at the c/EBP site. Interest-
ingly, this region (173 to 145)
may contain more than one CRE
element, as originally proposed by
Ray et al. (46), and this region is per-
haps more complex than depicted
by the figures presented in this
study and by other studies (23, 24).
The importance of the CRE and
c/EBP sites is further complicated
by the fact that CREB has weak
affinity for c/EBP and that c/EBP
may also bind CRE-like sequences
(48, 49). In fact, CRE and c/EBP sites
have been found in close proximity
in a number of genes (49–51) and
can act in concert to promote gene
transcription; hence, the biology of
these two sequences is often linked.
Further studies are required to iden-
tify the transcription factors that
mediated cAMP induction of IL-6
and how these transcription factors
interact with CRE or c/EBP
sequences.
Because cAMP and cAMP-elevating agents forskolin, an
adenylate cyclase activator, and rolipram, a phosphodiesterase
inhibitor, induced IL-6 protein and mRNA in BEAS-2B cells,
the data point to a cAMP-responsive kinase that may induce
transcriptional activation of the IL-6 gene. 2 agonists act via
adenylate cyclase, inducing intracellular cAMP, and this leads
to activation of several downstream pathways, including pro-
tein kinase A. Because we did not study the entire pathway
leading to IL-6 gene expression, it is unclear whether protein
kinase A or another kinase is responsible for inducing c/EBP or
CRE binding transcription factors. Because protein kinase A
can activate both CREB and c/EBP (51) transcription factors,
the role of protein kinase A in SM-induced IL-6 seems likely.
LABAs are powerful bronchodilators, and their use in
asthma and COPD is largely because of this effect. In conjunc-
tion with steroids, 2 agonists may also exhibit anti-inflamma-
tory and anti-proliferative effects, and recent in vitro evidence
suggests they are capable of exhibiting this property when used
alone (19, 21, 22, 47). There is much more to be explored
regarding the biology and immunoregulatory properties of 2
FIGURE 6.Modulation of RV16-induced IL-6 promoter activation by FP in BEAS-2B cells. A, FP suppressed
RV16-induced IL-6 promoter activation in a dose-dependent manner. B, FP suppressed promoter activation
using either a 651-bp parental promoter or a truncated 160-bp fragment. C, schematic diagram of the human
IL-6 promoter showing the location of two GRE-like sequences. The TATA proximal sequence was mutated by
site-directed mutagenesis producing the 651 GRE construct. D, the 651 GRE construct failed to respond to
FP treatment and did not suppress RV16-induced IL-6 promoter activation. All luciferase measurements were
normalized to constitutive -galactosidase measurements; n 4–5 experiments.
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agonists; this study and others have demonstrated that certain
cAMP-responsive genes may be up-regulated by 2 agonists.
Considering the beneficial properties of 2 agonists in asthma,
it is possible that some of the beneficial effect may be due to the
up-regulation of as yet unidentified CRE responsive genes as
well as the anti-inflammatory and bronchodilator effect. Fur-
ther studies are required to investigate which genes involved in
asthma and COPD are regulated by 2 agonists.
Whether IL-6 plays a helpful or harmful role in the context of
disease remains largely unanswered. Classically, IL-6 is cited as
a proinflammatory cytokine, the overproduction of which is
implicated in the pathology of many inflammatory disorders.
There is good evidence to suggest that IL-6 contributes to the
pathogenesis of rheumatoid arthritis and inflammatory bowel
diseases, such as Crohn disease. For example, IL-6 knock-out
mice are resistant to antigen-induced experimental arthritis
(52). Elevated IL-6 serum levels also correlate with the severity
of Crohn disease (53). The role of IL-6 in respiratory diseases,
however, is not so clear. IL-6 plays a role in O3-induced lung
injury and pulmonary inflammation yet is not involved in
O3-induced airway hyperresponsiveness (54). Furthermore,
transgenicmice overexpressing IL-6 had no effect on lung func-
tion (55). Meanwhile, in the endotoxic lung, IL-6 may have an
anti-inflammatory role as mice deficient in IL-6 have higher
levels of proinflammatory cytokines tumor necrosis factor-
and macrophage inflammatory protein-2 (56) and inflamma-
tory cells after exposure to an aerosolized allergen (57). The
above data suggest that whereas IL-6may have some inflamma-
tory properties in vivo, this does not affect airway function in
the abovemodels. Also, our data provide evidence that steroids
and2 agonists should be given together rather than as separate
treatments, as steroids potentially down-regulate potential
proinflammatory genes induce by 2 agonists.
In summary, GCs and 2 agonists have differing effects on
IL-6 transcription in bronchial epithelial cells. GCs suppress
IL-1 and RV-induced IL-6 via a unique mechanism involv-
ing an nGRE element proximal to the TATA box. In contrast,
2 agonists and cAMP elevating agents induce IL-6 and aug-
ment RV- and IL-1-induced IL-6 via c/EBP and/or CRE
sites within the IL-6 promoter. The data suggest that not all
proinflammatory genes are affected in the same manner by
GCs and 2 agonists and that an understanding of the tran-
scriptional regulation of proinflammatory genes can assist in
understanding how these two common asthma treatments
affect their expression.
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